22 recruiting, 19 completed, 10 terminated, 6 active not recruiting. 41 Phase 2, 26 Phase 1, 4 Phase 3, 3 Early Phase 1, 2 Phase 4.
Follow Clear-cell metastatic renal cell carcinoma: new trials by email Literature Review of Clear-cell metastatic renal cell carcinoma trials Research Report on Clear-cell metastatic renal cell carcinoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Low Dose, Reduced Frequency Nivolumab for the Treatment of Unresectable or Metastatic Cancer, AFFORD IO Trial Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging - Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage III Cutaneous Merkel Cell Carcinoma AJCC v8 | Phase 2 | Not yet recruiting | Fred Hutchinson Cancer Center | 50 | 2026-12-01 | 2026-09-17 |
| Zanzalintinib and MO-03 for the Treatment of Metastatic Renal Cell Cancer After Progression on Immunotherapy Biospecimen Collection, Bone Scan, C. butyricum CBM 588 Probiotic Strain Capsule Formulation MO-03 - Metastatic Clear Cell Renal Cell Carcinoma, Stage IV Renal Cell Cancer AJCC v8 | Phase 2 | Not yet recruiting | City of Hope Medical Center | 34 | 2026-11-28 | 2026-05-11 |
| Phase I Study Evaluating 161Tb-PSMA Therapy in Adult Patients With Metastatic Clear Cell Renal Cell Carcinoma 161Tb-PSMA-1 (radiopharmaceutical) - Metastatic Clear Cell Renal Cell Carcinoma | Phase 1 | Not yet recruiting | Centre Leon Berard | 26 | 2026-11-01 | 2026-09-18 |
| Casdatifan for the Treatment of Refractory Metastatic Clear Cell Renal Cell Carcinoma casdatifan - Refractory Clear Cell Renal Cell Carcinoma, Metastatic Clear Cell Renal Cell Carcinoma | Phase 1 | Recruiting | Vanderbilt-Ingram Cancer Center | 12 | 2026-09-21 | 2026-09-25 |
| TACTIC-RCC: Toripalimab Plus Axitinib Induction With Selective Deferred Cytoreductive Nephrectomy in TLS-Positive Advanced Clear Cell Renal Cell Carcinoma Toripalimab, Axitinib, Deferred Cytoreductive Nephrectomy - Metastatic Clear Cell Renal Cell Carcinoma, Advanced Clear Cell Renal Cell Carcinoma | Phase 2 | Not yet recruiting | Fudan University | 30 | 2026-08-20 | 2026-08-20 |
| RP2 and Tivozanib for the Treatment of Metastatic Renal Cell Cancer After Progression on Immunotherapy Biopsy Procedure, Biospecimen Collection, Computed Tomography - Advanced Clear Cell Renal Cell Carcinoma, Advanced Renal Cell Carcinoma | Phase 2 | Withdrawn | City of Hope Medical Center | 2026-08-11 | 2026-10-01 | |
| The Safety and Efficacy of Allogeneic CD70 CAR-T Therapy in Unresectable or Metastatic Clear Cell Renal Cell Carcinoma CLEAR CAR-T cell injection - Unresectable or Metastatic Clear Cell Renal Cell Carcinoma | Early Phase 1 | Recruiting | Chinese PLA General Hospital | 30 | 2026-07-01 | 2026-06-22 |
| CD70-Targeted Immuno-PET/CT-Directed Free of Therapy Used for mccRCC Patients With IMDC Favorable or Intermediate Risk PD-1/PD-L1 ICI + VEGFR-TKI, Treatment pause - Metastatic Clear Cell Renal Cell Carcinoma | Phase 2 | Recruiting | Jinling Hospital, China | 75 | 2026-06-16 | 2026-08-11 |
| Imaging Study in Metastatic Clear Cell RCC. RYZ512 - Metastatic Clear Cell Renal Cell Carcinoma | Early Phase 1 | Recruiting | RayzeBio, Inc. | 10 | 2026-06-15 | 2026-10-13 |
| Zanzalintinib for Metastatic Clear Cell Renal Cell Carcinoma With Bone Metastases Zanzalintinib, Investigator Choice of Bone Strengthening Agents (BSA), Non-Investigational Radiation Therapy (RT) - Clear Cell Renal Cell Cancer (ccRCC), Clear Cell Renal Carcinoma | Phase 2 | Recruiting | Kelly Fitzgerald, MD | 20 | 2026-06-10 | 2026-07-27 |
| Adding Biotherapy or Placebo to Standard Treatment for Advanced Kidney Cancer Axitinib, Biospecimen Collection, Bone Scan - Advanced Clear Cell Renal Cell Carcinoma, Metastatic Clear Cell Renal Cell Carcinoma | Phase 3 | Recruiting | SWOG Cancer Research Network | 718 | 2026-06-05 | 2026-06-11 |
| VSV-IFNβ-NIS With Ipilimumab and Nivolumab for the Treatment of Advanced or Metastatic Clear Cell Renal Cell Carcinoma Biopsy Procedure, Biospecimen Collection, Computed Tomography - Advanced Clear Cell Renal Cell Carcinoma, Metastatic Clear Cell Renal Cell Carcinoma | Phase 2 | Recruiting | Mayo Clinic | 18 | 2026-04-21 | 2026-06-05 |
| Radiopharmaceutical Treatment of Advanced Kidney Cancer 177Lu-PSMA-617 - Metastatic Clear Cell Renal Cell Carcinoma | Phase 2 | Recruiting | European Organisation for Research and Treatment of Cancer - EORTC | 48 | 2026-04-07 | 2026-06-04 |
| Immunotherapy (Nivolumab and Ipilimumab) With and Without a Live Biotherapeutic Product (EXL01) for the Treatment of Metastatic Renal Cell Cancer Biospecimen Collection, Bone Scan, Computed Tomography - Advanced Clear Cell Renal Cell Carcinoma, Advanced Sarcomatoid Renal Cell Carcinoma | Phase 1 | Recruiting | City of Hope Medical Center | 33 | 2026-03-23 | 2026-07-16 |
| Symbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell Cancer PF-08634404, Ipilimumab, Axitinib - Carcinoma, Renal Cell, Advanced Renal Cell Carcinoma | Phase 1 / Phase 2 | Recruiting | Pfizer | 224 | 2026-02-10 | 2026-10-08 |
| Dual-target CD70/CAIX CAR-NK Cells for Advanced Clear Cell Renal Cell Carcinoma EB-701/CA9-NK, Fludarabine - Advanced or Metastatic Clear Cell Renal Cell Carcinoma | Phase 1 / Phase 2 | Recruiting | Beijing Biotech | 36 | 2026-02-02 | 2026-04-24 |
| A First-in-Human Study of BMS-986506 in Participants With Advanced Clear Cell Renal Cell Carcinoma (ccRCC) BMS-986506, Pumitamig, Ipilimumab - Renal Cell Carcinoma | Phase 1 | Recruiting | Bristol-Myers Squibb | 281 | 2026-01-15 | 2026-08-11 |
| Open-Label Phase 1/2 Study of NEO-811 in Subjects With Locally Advanced or Metastatic Non-Resectable Clear Cell Renal Cell Carcinoma NEO-811 - Clear Cell Renal Cell Carcinoma, Renal Cell Carcinoma | Phase 1 | Recruiting | Neomorph, Inc | 30 | 2025-12-19 | 2026-10-05 |
| Safety and Efficacy of Yiwoxidan Anti (AK112) Monotherapy in Patients With Metastatic Renal Clear Cell Carcinoma Who Are Intolerant to TKI Treatment: a Prospective, Single Arm, Phase II Clinical Study Yivoximab - Renal Cell Carcinoma (RCC), Metastatic Clear Cell Renal Cell Carcinoma | Phase 2 | Enrolling by invitation | Sun Yat-sen University | 60 | 2025-11-01 | 2026-03-23 |
| PSMA Therapy and Immunotherapy in Kidney Cancer Pembrolizumab, 177Lu-PNT2002, (F-18)-DCFPyL - Metastatic Renal Cell Carcinoma, Metastatic Clear Cell Renal Cell Carcinoma | Phase 1 / Phase 2 | Withdrawn | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 2025-10-01 | 2025-08-19 |
Showing 20 of 71. Sign in to see all of them.
Carcinoma, Renal Cell (44) · Kidney Neoplasms (13) · Neoplasm Metastasis (8) · Carcinoma, Non-Small-Cell Lung (5) · Melanoma (4) · Neoplasms (3) · Carcinoma, Transitional Cell (2) · Colorectal Neoplasms (2) · Head and Neck Neoplasms (2) · Kidney Diseases (2) · Neoplasms by Histologic Type (2) · Prostatic Neoplasms (2) · Triple Negative Breast Neoplasms (2) · Urogenital Neoplasms (2)
Neoplasms by Site (51) · Female Urogenital Diseases (49) · Female Urogenital Diseases and Pregnancy Complications (49) · Male Urogenital Diseases (49) · Neoplasms (49) · Urogenital Diseases (49) · Kidney Diseases (47) · Urogenital Neoplasms (47) · Urologic Diseases (47) · Urologic Neoplasms (47) · Neoplasms, Glandular and Epithelial (45) · Adenocarcinoma (44) · Neoplasms by Histologic Type (44) · Carcinoma (43) · Kidney Neoplasms (36)
Nivolumab (15) · Ipilimumab (12) · Specimen Handling (10) · Sunitinib (9) · Axitinib (7) · CTLA-4 Antigen (7) · Magnetic Resonance Spectroscopy (6) · cabozantinib (6) · pazopanib (6) · pembrolizumab (6) · Biopsy (4) · Everolimus (4) · Radiosurgery (3) · Blood Specimen Collection (2) · Radiopharmaceuticals (2)
City of Hope Medical Center (4) · Association Pour La Recherche des Thérapeutiques Innovantes en Cancérologie (3) · M.D. Anderson Cancer Center (3) · Bristol-Myers Squibb (2) · Celldex Therapeutics (2) · Centre Leon Berard (2) · Mayo Clinic (2) · Pfizer (2) · Radboud University Medical Center (2) · SWOG Cancer Research Network (2) · Sunnybrook Health Sciences Centre (2) · University of Texas Southwestern Medical Center (2) · Vanderbilt-Ingram Cancer Center (2) · AIO-Studien-gGmbH (1) · Abramson Cancer Center at Penn Medicine (1)
United States (38) · France (12) · Canada (8) · China (8) · Italy (6) · Spain (6) · Germany (4) · United Kingdom (4) · Australia (3) · Czechia (3) · Netherlands (3) · Poland (3) · Austria (2) · Belgium (2) · Japan (2)
Sumanta K Pal (3) · Raquibul Hannan, MD, PhD (2) · Alex Chehrazi-Raffle, MD (1) · Ana Aparicio (1) · Andrew W Hahn, MD (1) · Arsenal Biosciences (1) · Brian A. Costello, MD (1) · Brian I Rini, MD (1) · Brian Rini (1) · Charles B Nguyen (1) · David Y Oh, MD, PhD (1)
PMID 24308791, PMID 26706103, PMID 27101285, PMID 27154357, PMID 30348216, PMID 30648632, PMID 32203306, PMID 32620212, PMID 32738823, PMID 33742979, PMID 35310961, PMID 35390339, PMID 37093350, PMID 37335139, PMID 37844597, PMID 38302933, PMID 38314087, PMID 38942995, PMID 38961439, PMID 40212021, PMID 40791544, PMID 41073165, PMID 41484629, PMID 41673778, PMID 42246926, PMID 42447427
P30CA033572 (5), 2015 (2), 2025 (2), K12CA270377 (1), P30CA015083 (1), P30CA068485 (1), U10CA180888 (1)